IGHE and allergic asthma: Omalizumab is the first mAb approved by the European Medicines Agency (EMA) and FDA for the treatment of patients ≥6 years old with persistent severe allergic asthma, high levels of blood IgE, and at least a sensitization to a perennial allergen [49].